The genetic basis for inactivation of Wnt pathway in human osteosarcoma by Xiaoling Du et al.
Du et al. BMC Cancer 2014, 14:450
http://www.biomedcentral.com/1471-2407/14/450RESEARCH ARTICLE Open AccessThe genetic basis for inactivation of Wnt pathway
in human osteosarcoma
Xiaoling Du1,2,4†, Jilong Yang2,3*†, Da Yang3†, Wei Tian2 and Ze Zhu4*Abstract
Background: Osteosarcoma is a highly genetically unstable tumor with poor prognosis. We performed microarray-based
comparative genomic hybridization (aCGH), transcriptome sequencing (RNA-seq), and pathway analysis to gain a
systemic view of the pathway alterations of osteosarcoma.
Methods: aCGH experiments were carried out on 10 fresh osteosarcoma samples. The output data (Gene Expression
Omnibus Series accession number GSE19180) were pooled with published aCGH raw data (GSE9654) to determine
recurrent copy number changes. These were analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis to identify altered pathways in osteosarcoma. Transcriptome sequencing of six osteosarcomas was
performed to detect the expression profile of Wnt signaling pathway genes. Protein expression of WNT1, β-catenin,
c-myc, and cyclin D1 in the Wnt pathway was detected by immunohistochemistry (IHC) in an independent group of
46 osteosarcoma samples.
Results: KEGG pathway analysis identified frequent deletions of Wnt and other Wnt signaling pathway genes. At the
mRNA level, transcriptome sequencing found reduced levels of mRNA expression of Wnt signaling pathway transcripts.
While WNT1 protein expression was detected by IHC in 69.6% (32/46) of the osteosarcomas, no β-catenin protein was
detected in the nucleus. β-catenin protein expression was, however, detected in the membrane and cytoplasm of
69.6% (32/46) of the osteosarcomas. c-myc protein expression was detected in only 47.8% (22/46) and cyclin D1 protein
expression in 52.2% (24/46) of osteosarcoma samples. Kaplan-Meier survival analysis showed that WNT1-negative
patients had a trend towards longer disease free survival than WNT1-positive patients. Interestingly, in WNT1-negative
patients, those who were also cyclin D1-negative had significantly longer disease free survival than cyclin D1-positive
patients. However, there was no significant association between any of the investigated proteins and overall survival of
human osteosarcoma patients.
Conclusions: Frequent deletions of Wnt and other Wnt signaling pathway genes suggest that the Wnt signaling
pathway is genetically inactivated in human osteosarcoma.
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Osteosarcoma is a malignant bone tumor, often associa-
ted with copy number alterations, that most commonly
arises in the metaphyseal ends of long bones [1-3]. The
survival of patients with osteosarcoma has not improved
significantly in recent years and the prognosis of patients* Correspondence: yangjilong@tjmuch.com; zhuze_2006@126.com
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Identification of prognosis markers and key genetic and
molecular events for osteosarcoma is critical for devel-
opment of effective therapeutics [2,3].
Fortunately, the discovery of signal transduction path-
ways and their importance in a variety of cancers has led
to the development of many new targeted agents. With
regard to osteosarcoma, preclinical investigations tar-
geting the rapamycin (mTOR) pathway, as well as the
VEGF pathway showed promising results [2,4]. The Wnt
pathway is clearly important in many forms of human
cancer, particularly in epithelial cancer types where gain-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inherited cancer risk and somatic carcinogenesis [5]. In
human osteosarcoma, most previous studies have sug-
gested that active Wnt signaling contributes to osteo-
sarcoma development, evidenced by cytoplasmic and/or
membranous β-catenin staining or detection of Wnt
pathway components [6,7]. However, Cai and colleagues
recently reported that the Wnt pathway is inactivated in
osteosarcomas [8]. These contradictory findings provoke
debate and stimulate further research into the role of
Wnt signaling in osteosarcoma [5].
In this study, we sought to gain a comprehensive under-
standing of the key driving pathways for osteosarcoma
by performing pathway analysis of recurring gene copy
number aberrations using array comparative genomic
hybridization (aCGH) analysis. Transcriptome sequencing
(RNA-seq) and immunohistochemistry (IHC) were used to
explore the expression level of key signaling pathways af-
fected by these genetic aberrations. The most surprising
and intriguing finding was the deletion of Wnt pathway
genes, suggesting the genetic inactivation of the Wnt sig-
naling pathway, in human osteosarcoma.
Methods
Osteosarcoma tissues and clinical information
Ten frozen osteosarcoma biopsy samples, all with at
least 90% tumor content, were obtained from the Tissue
Bank of the Tianjin Medical University Cancer Institute
& Hospital (TMUCIH) for aCGH and RNA-Seq analysis
as described below. Tumor samples were snap frozen in
liquid nitrogen. In addition, an independent group of
46 primary osteosarcoma cases with formalin-fixed and
paraffin-embedded (FFPE) tissues and clinicopathologic
data were collected. All of the tissues and information
collection took place at Tianjin Medical University
Cancer Institute & Hospital (TMUCIH) with Institu-
tional Review Board (IRB) approved protocols and the
patients’ consent. The clinical and pathological param-
eters included age, gender, locations, Enneking sta-
ging, and follow-up data (Table 1). All neoadjuvant and
adjuvant chemotherapy had been administered according
to the Rosen T10 regimen [9,10]. Disease-free and overall
survival time ranged from 0 to 94 months, with medians
of 9 and 13 months, respectively.
Array comparative genomic hybridization and pathway
enrichment analysis
The aCGH data analysis was performed as previously
described [2,3]. aCGH data in this publication have been
deposited in NCBI’s Gene Expression Omnibus (GEO)
and are accessible through GEO Series accession num-
ber GSE19180. In addition, we obtained the raw aCGH
data of another 10 osteosarcoma biopsy samples from
the GEO database (GSE9654) [11] and pooled the twodatasets for analysis. Briefly, the median-normalized log-
2 ratio data were first subjected to a circular binary seg-
mentation (CBS) algorithm to reduce the effect of noise
[12]. Then, the CGHcall algorithm was used to call seg-
ments of DNA sequences as amplified or deleted in each
sample [13]. A permutation analysis was further applied
to call recurrent copy number aberration in osteosar-
coma [2]. As a result of this procedure, each target was
given a label of “normal”, “deletion” or “amplification” as
previously described [2,3,13]. A bacterial artificial chromo-
some (BAC) clone–based CGH array dataset from 36
cases of osteosarcoma was also analyzed to confirm the
overall recurrent gene copy alteration patterns [2,3,14].
Pathway enrichment analysis was performed separately
on the recurrent amplified and deleted gene lists from
gene sets GSE19180 and GSE9654 as previously reported
[2,3]. Here, we used the gene annotations data in the
Kyoto Encyclopedia of Genes and Genomes (KEGG).
Pathways with more annotations in our gene list than
expected by random (hypergeometric model, P < 0.05)
were considered to be significantly enriched with ampli-
fied or deleted genes [2,3].
RNA-seq analysis
Frozen tumors were crushed, then total RNA was iso-
lated using TRIzol reagent (Invitrogen, Grand Island,
NY). RNA was quantified by Qubit (Invitrogen, Grand
Island, NY) and Nanodrop ND1000 (ThermoFisher
Scientific, Waltham, MA) before quality assessment with
the Agilent 2100 Bioanalyzer. Six of the 10 samples with
high quality RNA were used for RNA library construction,
followed by emulsion PCR and whole transcriptome 90 bp
paired-end sequencing on Illumina HiSeq™ 2000 instru-
ments at the Beijing Genomics Institute (BGI, Shenzhen,
China). Each sequencing run produced approximately 50
million paired end reads.
Whole transcriptome sequencing reads were aligned
against the GRCh37 human reference genome using
Tophat version 2.0.4 [15]. The number of overlapping
reads was calculated for all exons and then for all genes
annotated in Ensembl 67. Gene expression values
were normalized across samples using median-of-ratios
normalization [16]. Briefly, an expression ratio between
two samples for every gene (or exon) with > 500 reads is
calculated, and the median of those ratios is determined.
All gene expression values are then multiplied by the
median-of-ratios.
Immunohistochemical analysis of WNT1, β-catenin, c-myc,
and cyclin D1 expression
The 46 FFPE tissues were sectioned at 4 μm and mounted
onto charged glass slides (ProbeOn Plus, Fisher Scientific,
Pittsburgh, PA, USA) for immunohistochemical staining as
described previously [2]. Briefly, tissues were deparaffinized
Table 1 The clinical and pathological features in 46 human conventional osteosarcomas
N Disease free survival Overall survival
P HR 95.0% CI P HR 95.0% CI
L U L U
Sex Male 29 0.86 0.07*
Female 29 0.86 1.11 0.36 3.44 0.08 3.49 0.86 14.28
Age group <=15 y 14 0.76 0.79
15-20 y 23 0.94 1.10E + 04 0 1.40E + 116 0.5 1.82 0.32 10.42
21-30 y 11 0.94 3.70E + 04 0 4.40E + 116 0.72 0.73 0.13 4.05
31-40 y 1 0.93 5.30E + 04 0 6.40E + 116 0.97 0 0 1.90E + 282
>40 y 9 1 1.02 0 3.90E + 225 0.99 0 0
Tumor location limbs 51 0.28 0.97
Others 7 0.48 23.34 0.004 1.60E + 05 0.97 0.97 0.12 7.72
Enneking stage I 4 0.96 0.43
IIA 19 0.78 0.71 0.06 7.88 0.17 0.1 0.004 2.74
IIB 2 0.631 0.59 0.07 5.01 0.1 0.09 0.01 1.61
III 1 0.897 0.83 0.05 13.39 0.99 0 0
Neoadjuvant chemotherapy No 10 0.51 1.5E-4*
Yes 30 0.51 1.51 0.44 5.15 0.003 11.85 2.36 59.45
Adjuvant chemotherapy No 3 0.21 0.41
Yes 19 0.43 0.04 0 129.34 0.61 0.04 0 1.20E + 04
Recurrence No 50 0.49
Yes 8 0.49 2.05 0.26 16.26
Metastasis No 38 0.045*
Yes 11 0.436 0.01 0 2.40E + 03
*Significantly different; L: lower; U: upper.
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vity was blocked with 0.3% H2O2 (Fisher Scientific,
Fair Lawn, NJ, USA). Tissues were blocked for 30 min
with normal serum (Vector Laboratories, Burlingame,
CA, USA) and then incubated overnight at 4°C with
appropriate antibodies. Antibodies for WNT1, β-catenin,
c-myc, and cyclin D1 (Abcam, Cambridge, UK) were used
at a dilution of 1:200, 1:100, 1:100, and 1:100, respectively.
The same concentrations of non-immune rabbit serum
were used as negative controls. Signal was detected using
biotinylated anti-rabbit antibodies, followed by avidin,
biotinylated enzyme and colorimetric detection using
3,3′-diaminobenzidine tetrahydrachloride (DAB) (DAKO
Corporation, Carpinteria, CA, USA). Samples were then
counterstained with Mayer’s hematoxylin (Polyscientific,
Bay Shore, NY, USA).
Two pathologists, blinded to clinical information, eva-
luated and scored the immunohistochemical staining for
WNT1, β-catenin, c-myc, and cyclin D1 in osteosarcoma
tissues based on the overall intensity of membranous,
cytoplasmic, and nuclear staining within the tumor cells
and the percentage of cells stained [8,17-20]. WNT1 andβ-catenin staining were scored as described in [8,17].
Specifically, intensity of staining was graded as follows: lost
(score 0); weak (“+”, score 1); moderate (“++”, score 2);
and strong (“+++”, score 3). Extent of staining was eva-
luated as the percentage of positive cells per 100 or more
cells (at least 100 cells in 10 high-power fields) in each
evaluated compartment and was graded into five classes as
follows: < 5% (score 0); 6% to 25% (score 1); 26% to 50%
(score 2); 51% to 75% (score 3); > 75% (score 4). A final
staining score was calculated by adding intensity score and
extent score for each compartment, and the expression
was categorized into two classes based on the final score:
positive (final score 2–7) and negative (final score 0–1) ex-
pression. For β-catenin staining evaluation, any intensity
and extent of staining found in the nucleus was con-
sidered positive. The staining of c-myc and cyclin D1 was
assessed on the basis of published data: negative (< 10% of
the cells), and positive (> 10% of the cells) [18-20].
Statistics
Student’s t-test, ANOVA, Chi-square, Fisher’s exact test,
Kaplan-Meier, and Mantel-Cox survival analysis were
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sary. A P value of less than 0.05 was considered statisti-
cally significant in multivariate analysis.
Results
Several signaling pathways are genetically altered in
osteosarcoma
As presented in our previous reports, high-density genome-
wide aCGH profiling (GSE19180) of 10 osteosarcoma tis-
sues identified several major regions with significant genetic
alterations. This pattern of copy number alterations was
strikingly similar to that from an independent aCGH data-
set (GSE9654) of osteosarcoma samples obtained from
Canadian patients [2,3,11]. It was therefore reasonable to
pool the two aCGH datasets (GSE19180 and GSE 9654) for
further pathway analysis. Analysis of the combined dataset
led to the identification of the amplification of 2,519 genes
and deletion of 1,276 genes among the 20 osteosarcoma
samples (Figure 1A). We also analyzed a BAC clone-
based, aCGH dataset from 36 Norwegian osteosarcoma
samples (Figure 1B) [14]. The analysis of this third dataset
showed similar results to the first 20 aCGH osteosar-
comas, suggesting consistent genetic alterations under-
lying the pathogenesis of osteosarcoma.
The GSE19180 and GSE9654 datasets were measured
on Agilent Human Genome CGH Microarrays, while the
third aCGH dataset was BAC clone-based. Therefore the
KEGG pathway enrichment analysis was only performed
on dataset GSE19180 and GSE9654. In the KEGG pathway
enrichment analysis, significant genetic amplifications
were identified in the component genes of 20 signaling
pathways including the VEGF, mTOR, CAMs, and ad-
herens junction signaling pathways. Significant genetic
deletions were identified in the component genes of 11Figure 1 Genetic aberrations in human osteosarcoma samples. The x-
denotes log-ratio for every aCGH probe (scatter plot). The y-axis shows rec
measured sequence aligned evenly in chromosomal order on the x-axis. Re
the locations of significantly recurrent aberrations. Red denotes significantly rec
Gray represents nonsignificant recurrence of aberrations. A. Genetic aberration
36 Norwegian osteosarcoma samples.signaling pathways including the Wnt and Hedgehog
signaling pathways (Tables 2 and 3). In our previous stu-
dies, the integrated methods of aCGH, fluorescent in situ
hybridization (FISH), and IHC has led to validation of the
genetic amplification of VEGF pathway genes [2].
Wnt pathway genes are deleted in human osteosarcomas
In contrast to the amplification of VEGF pathway genes,
we detected significant over-representation of deleted
genes in 11 pathways. Among these pathways, the Wnt
signaling pathway was most highly affected (Table 3). This
is the first description of this genetic aberration in human
osteosarcoma. As controversy exists in the field as to
whether the Wnt signaling pathway is inactivated or not
in osteosarcoma [8,21], we further investigated copy num-
ber alterations of individual genes in the Wnt signaling
pathway. In the canonical Wnt signaling pathway, the fol-
lowing genes were significantly deleted across the osteo-
sarcoma dataset: WNT, FRP, Frizzled, GBP, GSK-3β, TCF/
LET, TAK1, CK1, CtBP, and B-TrCP (Figure 2). Specifi-
cally, the WNT1 gene was deleted in 10 cases of the 20
human osteosarcomas with a deletion frequency of 50%.
Reduced transcript and protein expression of Wnt
signaling pathway components suggests the Wnt
signaling pathway is inactivated in human osteosarcomas
To determine whether there was an association between
gene copy number and mRNA expression of Wnt pathway
genes, we compared transcriptome sequencing data of six
osteosarcoma samples (Additional file 1) with aCGH ana-
lysis performed on their genomic DNA (Additional file 2).
We found that the deletion of certain genes was associated
with low mRNA expression, such as NLK, SOX1, MAPK8,
MAP1B, and FZD7 genes (Figure 3).axis numbered with 1–22 denotes chromosome numbers. The y-axis
urrence of gains (positive axis) and losses (negative axis) for each
currence rates that exceed the threshold are color-coded to emphasize
urrent amplifications and green denotes significantly recurrent deletions.
s of 20 osteosarcomas (GSE19180 and GSE9654). B. Genetic aberrations of
Table 2 Genetic amplifications of key pathway genes in osteosarcoma
KEEG pathways P-value Gene name cohort
VEGF signaling pathway 0.000611811 MAPK14, AKT1, PLA2G2D, PLA2G2E, NFATC4, PIK3CD, PLA2G2A, PLA2G5, MAPK1, MAPK13, PTK2,
RAC1, RAC3, PLA2G2F, VEGFA, CASP9, PIK3R3, SPHK1, SH2D2A, CDC42P2, CDC42
mTOR signaling pathway 0.024894273 AKT1, MTOR, RICTOR, PIK3CD, PRKAA1, PRKAA2, MAPK1, RPTOR, RPS6KA1, VEGFA, PIK3R3, ULK2
Tight junction 0.044332801 INADL, EXOC3, CSNK2B, CLDN19, AKT1, CLDN14, CLDN17, LLGL2, LLGL1, MYH6, MYH7, F11R, ASH1L,
PRKCZ, CGN, JAM2, RAB3B, RAB13, ACTB, ACTG1, CLDN5, CLDN8, CRB3, TJAP1, CDC42P2, CDC42
Synthesis and degradation
of ketone bodies
0.019871373 HMGCL, HMGCS1, HMGCS2, OXCT1
C21-Steroid hormone metabolism 0.04221587 CYP11B1, CYP11B2, HSD3B1, HSD3B2
Peptidoglycan biosynthesis 0.017208179 PGLYRP2, PGLYRP3, PGLYRP4
Ether lipid metabolism 0.006547877 AGPAT1, PLA2G2D, PLA2G2E, PAFAH2, ENPP2, PLA2G2A, PLA2G5, AGPAT3, PLA2G2F, PPAP2B
Arachidonic acid metabolism 0.02227667 CYP2J2, CYP4A11, GPX6, PLA2G2D, GPX5, GPX7, PLA2G2E, CYP4F3, PLA2G2A, PLA2G5, PLA2G2F,
CYP4F2, CBR3
Alpha-Linolenic acid metabolism 0.003362937 PLA2G2D, PLA2G2E, ACOX1, PLA2G2A, PLA2G5, PLA2G2F, FADS2
Nitrogen metabolism 0.007842327 CTH, CA14, CA1, CA2, CA3, CA6, CA8, ASRGL1
Glycan structures-biosynthesis 2 0.025972282 PIGK, B3GALT5, ST6GALNAC3, PIGP, PIGV, ST3GAL1, ST3GAL3, ST6GALNAC5, B4GALT3, B4GALT2,
B3GALT4, GPAA1, PIGM, PIGL
Biosynthesis of unsaturated
fatty acids
0.021314211 ACOT7, FASN, ACOT11, FADS1, ACOX1, FADS2, TECR
Antigen processing and
presentation
0.028228218 CTSS, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DQA2, HLA-DRB5, HLA-F,
HSPA1B, HSPA1A, HSPA1L, HSP90AB1, NFYA, NFYC, RFX5, TAP1, TAP2, CALR
Fc epsilon RI signaling pathway 0.000481297 MAPK14, AKT1, FCER1A, FCER1G, PLA2G2D, GRB2, PLA2G2E, LYN, PIK3CD, PLA2G2A, PLA2G5,
MAPK1, MAPK13, MAP2K3, MAP2K7, RAC1, RAC3, PLA2G2F, TNF, VAV1, PIK3R3
Insulin signaling pathway 0.047775005 FLOT1, CRKL, AKT1, FASN, EXOC7, MTOR, GRB2, INSR, PFKL, PIK3CD, PKLR, PRKAA1, PRKAA2,
PRKAB2, PRKACA, PRKACB, PRKCZ, MAPK1, RPTOR, PTPRF, SHC1, SREBF1, PIK3R3, MKNK1, TRIP10
GnRH signaling pathway 0.04873803 ADCY8, MAPK14, ADCY4, PLA2G2D, GRB2, PLA2G2E, ITPR3, JUN, PLA2G2A, PLA2G5, PRKACA,
PRKACB, MAPK1, MAPK7, MAPK13, MAP2K3, MAP2K7, PLA2G2F, CDC42P2, CDC42
Alzheimer’s disease 0.020850782 NCSTN, BACE2, APP, APH1A, C1QA, TNF, C1QB, C1QC
Asthma 0.003038215 FCER1A, FCER1G, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DQA2, HLA-DRB5, TNF
Systemic lupus erythematosus 2.49E-06 FCGR1A, FCGR2A, FCGR2B, FCGR3A, HIST1H2AB, HIST1H2AE, HIST1H2BD, H3F3B, H3F3A, HLA-DMA,
HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DQA2, HLA-DRB5, HIST2H2AB, C1QA, TNF, C1QB,
C1QC, C2, C3, C6, C7, C8A, C8B, C9, HIST1H2AG, SMCHD1, HIST1H2AI, HIST1H2AK, HIST1H2AL,
HIST1H2AM, HIST1H2AJ, HIST1H2AC, HIST2H2AC, HIST1H2BC, HIST1H2BE, HIST1H2BF, HIST1H2BG,
HIST1H2BI, HIST1H2BO, HIST2H2BE, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F,
HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST4H4, HIST1H4A, HIST1H4B, HIST1H4C, HIST1H4D,
HIST1H4E, HIST1H4F, HIST1H4H, HIST1H4I, HIST1H4J, HIST1H4K, HIST1H4L, HIST2H4A, HIST2H4B,
HIST1H4G, HIST1H2AH, HIST1H2BK, HIST1H2BJ
Allograft rejection 0.046891168 HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DQA2, HLA-DRB5, HLA-F, TNF
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ling pathways and its effect on the downstream sig-
naling, WNT1, β-catenin, c-myc, and cyclin D1 protein
expression was measured by IHC in 46 osteosarcoma
samples (Figure 4A-D). WNT1 protein expression was
detected predominantly in cytoplasm. β-catenin protein
expression was observed in the membrane and cyto-
plasm but not in the nucleus. c-myc and cyclin D1 pro-
tein expression were detected in the nucleus. No protein
expression was detected in negative control samples.
WNT1 protein expression was detected in 69.6% (32/46)
of the osteosarcomas (Figure 4A), however no β-catenin
protein expression was observed in the nucleus (Figure 4B).
β-catenin protein expression was detected in the membraneand cytoplasm of 69.6% (32/46) of the osteosarcomas
(Figure 4B), negative c-myc protein expression was re-
corded for 52.2% (24/46) of osteosarcomas and negative
cyclin D1 protein expression was recorded for 47.8%
(22/46) of osteosarcomas (Figure 4C-D). Compared with
previously published reports of c-myc and cyclin D1 ex-
pression frequencies in other tumors, such as endo-
metrial carcinoma [22,23], these detection frequencies
(47.8% (22/46) c-myc-positive and 52.2% (24/46) cyclin
D1-positive) are low. Combined with the low levels of
mRNA expression for Wnt pathway genes, these data,
especially the lack of β-catenin protein expression in the
nucleus, suggest that the Wnt signaling pathway may be
inactive.
Table 3 Genetic deletions of key pathway genes in osteosarcoma
KEEG pathways P value Gene name cohort
Wnt signaling pathway 0.01039 FRAT1, CSNK1A1L, CTBP2, PRICKLE2, FRAT2, GSK3B, PLCB2, SFRP5, MAP3K7,
TCF7L2, WNT5A, WNT6, WNT8B, FZD5, WNT10A, FZD7, FZD8, BTRC
Hedgehog signaling pathway 0.012811 CSNK1A1L, STK36, GSK3B, SUFU, WNT5A, WNT6, WNT8B, WNT10A, BTRC
Adherens junction 0.014329 SORBS1, WASF3, FER, FYN, PVRL3, MLLT4, PARD3, MAP3K7, TCF7L2, VCL, WASF1
Metabolism of xenobiotics by cytochrome P450 0.006437 AKR1C4, GSTO2, CYP2C19, CYP2C8, CYP2C9, CYP2C18, AKR1C1, AKR1C2,
UGT1A8, AKR1C3, GSTO1
PPAR signaling pathway 0.039963 SORBS1, CYP27A1, FABP7, ACSL3, ACADL, ME1, ACSL5, SCD, ACOX2
Non-homologous end-joining 0.001607 DNTT, POLL, DCLRE1C, XRCC5, NHEJ1
Phosphatidylinositol signaling system 0.040426 DGKH, INPP5D, PLCE1, CALML5, PIK3R1, GNG7, PIP4K2A, PLCB2, PTEN, PLCD4, DGKD
ECM-receptor interaction 0.032505 COL6A3, FNDC3A, SV2C, FN1, ITGA1, ITGB1, LAMA4, THBS1, THBS2, ITGA8, CD47
T cell receptor signaling pathway 0.020903 RASGRP1, CHUK, MAP3K8, CTLA4, FYN, ICOS, NFKB2, PIK3R1, PRKCQ, PAK6, CBLB, CD28
Melanogenesis 0.007761 ADCY5, CREB1, GSK3B, MITF, CALML5, PLCB2, TCF7L2, WNT5A, WNT6, WNT8B,
FZD5, WNT10A, FZD7, FZD8
Basal cell carcinoma 0.00088 STK36, GSK3B, SUFU, TCF7L2, WNT5A, WNT6, WNT8B, FZD5, WNT10A, FZD7, FZD8
Figure 2 Visualization of the location of altered genes in the Wnt pathway. Pink indicates genes with significantly recurrent amplification,
and green denotes genes with significantly recurrent deletion. White indicates genes with no significant aberrations.
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Figure 3 mRNA expression of genes in the Wnt signaling pathway. Circle color indicates copy number (red are amplified, blue are deleted).
Circle size indicates mRNA expression level calculated based on RNA-seq reads. Absolute expression: the size of circles is based on the absolute read count
(Left panel). Normalized expression: the size of circles is relative to the average expression (Right panel). Primary data for aCGH and RNA-seq can be found
in Additional files 1 and 2.
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Figure 4 Protein expression of the Wnt signaling pathway and its role in survival. A. WNT1 protein expression (IHC, 10 × 40). B. β-catenin
protein expression (IHC, 10 × 40). C. c-myc protein expression (IHC, 10 × 40). D. Cyclin D1 protein expression (IHC, 10 × 40). E. Disease free time of
WNT1-negative patients was not significantly longer than WNT1-positive patients. F. K-M survival analysis showed that patients negative for both
WNT1 and cyclin D1 expression had significantly longer disease free survival time.
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with longer disease-free survival
While the expression of WNT1, β-catenin, c-myc, and
cyclin D1 had no correlation with clinicopathological
factors, WNT1 expression had significant positive cor-
relation with β-catenin (χ2 = 15.97, P = 0.001, Pearson’s
R = 0.59), c-myc (χ2 = 5.62, P = 0.018, Pearson’s R = 0.35),
and cyclin D1 expression (χ2 = 11.58, P = 0.001, Pearson’s
R = 0.50). β-catenin protein expression had significant
positive correlation with c-myc (χ2 = 5.62, p = 0.018,
Pearson’s R = 0.35) and cyclin D1 (χ2 = 16.36, p = 5.25E-5,
Pearson’s R = 0.6). Because β-catenin is a key mediating
factor and c-myc/cyclin D1 are key targets regulated by
the Wnt signaling pathway, these consistent relationshipssuggest that the initial signal, mediating factor, and down-
stream events of the Wnt signaling pathway may all be
inactivated in human osteosarcoma.
To detect the effect of the Wnt signaling pathway on
survival, the disease-free and total survival of patients
were analyzed. Even though single protein expression of
β-catenin, c-myc and cyclin D1 showed no significant ef-
fect on disease-free survival, K-M survival analysis showed
that WNT1-negative patients had a trend towards longer
disease-free survival than WNT1-positive patients, al-
though this was not statistically significant (Log Rank =
2.452, P = 0.117) (Figure 4E).
Patients negative for all of WNT1, β-catenin and cyclin
D1/c-myc protein expression might be considered to have
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vival of such patients will reflect the effect of inactivation
of the Wnt signaling pathway on survival. Indeed, our data
showed that in the patients who were negative for WNT1
protein expression, those who were also negative for cyclin
D1 expression had significantly longer disease-free sur-
vival than patients with positive cyclin D1 expression (Log
Rank = 3.884, P = 0.049) (Figure 4F). However, expression
of none of the proteins examined had significant cor-
relation with the overall survival of human osteosarcoma
patients.
Discussion
In this study we describe, for the first time, significant dele-
tion of genes involved in the Wnt signaling pathway, imply-
ing genetic inactivation of this important signaling pathway,
in human osteosarcoma. Supporting this, transcriptome
analysis determined that mRNA expression of genes in the
Wnt signaling pathway was reduced. In addition, at the
protein level, nuclear β-catenin expression was not ob-
served and c-myc/cyclin D1 protein were detected at lower
frequencies compared with the frequencies observed in
other tumors. Our results are in agreement with published
data from Cai and colleagues, who reported that the Wnt
pathway is inactivated in bone cancers [8]. Furthermore,
similar results were reported by Matushansky and Gregory,
indicating that inactivation of the Wnt pathway contributes
to tumorigenesis in so-called malignant fibrous histiocy-
toma and melanoma [17,21,24]. In contrast to these results,
most previous studies have suggested that active Wnt sig-
naling contributes to osteosarcoma development [6,7].
Furthermore, it is reported that the Wnt pathway is tran-
scriptionally active in radiation-induced rat osteosarcomas
[25], and that the Wnt/β-catenin pathway antagonists, cur-
cumin and PKF118-310, demonstrate anti-tumor activity
against human osteosarcoma cells [26]. These seemingly
conflicting results suggest that the complexity of this
important signaling pathway is still poorly understood in
human osteosarcoma [5].
An interesting but unanswered question raised in the
present study is: at which time during osteosarcoma pro-
gression is the Wnt signaling pathway inactivated. As in-
activation of the Wnt signaling pathway is associated
with longer disease-free survival, it suggests that this in-
activation may occur at an early time point in osteosar-
coma progression. However, more investigations in vivo
and in vitro are required before this question can be
answered.
Conclusions
Based on evidence at the genomic, our data suggest that
the Wnt signaling pathway may be genetically inacti-
vated in osteosarcoma. These results remind us of the
complexity of this important signaling pathway.Additional files
Additional file 1: Gene differential expression of osteosarcoma
samples.
Additional file 2: The significant deletion of Wnt signal pathway
genes.
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